فاس نيوز ميديا جريدة الكترونية جهوية تعنى بشؤون و أخبار جهة فاس مكناس – متجددة على مدار الساعة
A report attributed to the Moroccan Network for the Defense of the Right to Health and Life revealed rising drug prices in Morocco, sparking widespread debate in health and media circles.
The report focuses on increased prices of imported medications used to treat chronic diseases, such as heart conditions, asthma, hepatitis, and cancer. The source cited an example of a hepatitis medication priced between 3,000 and 6,000 dirhams in Morocco, compared to just 800 dirhams in Egypt.
The report attributed these high prices to the monopoly of certain exporters controlling approximately 25% of imported drugs.
The Moroccan Federation of Pharmaceutical Industries and Innovation (FMIIP) denied these claims. Layla Sentissi, the federation’s executive director, emphasized that drug pricing is strictly regulated by the state, referencing a 2014 decree that establishes drug pricing mechanisms based on indicators from seven countries.
Concurrent with this debate, the former Minister of Health, Khalid Ait Taleb, announced price reductions for some medications by up to 59% for chronic diseases.
The question remains open about the transparency and effectiveness of drug price control mechanisms in Morocco, given the clear divergence between the civil organization’s narrative and the pharmaceutical sector’s assertions.
